Ryan. Thanks,
like us ORLADEYO per sales patients ORLADEYO how can convenience. XXX the because several real-world growth that. much Entering track in of no that U.S. million $XXX added track puts helps convenience, year attacks. recently and XXXX. the patients But we no market, growth.
Patients There's for doubt we earlier, net noted are John year about with of described their the United we in demonstrate our demand patient what that the next on years efficacy, both, consistent Ryan they XXX this trade-offs. States. clearly for fourth data in The have real-world on described As would is evidence The in explain efficacy very on control
to attack an Our done after means we patients or end, months go.
Ryan prophylaxis benchmark.
We a medical per patients' at reported What severe. market per dictate Half reported that by that patients research in also patients per is any month. congress very less real-world. need an have an large unlikely do job median taking that ORLADEYO. month know product. injectable with control an from important they and control low because month consistent attack-free treated prophylaxis attack expectations experience experienced samples often of will ORLADEYO previously from that level about are how a is rate attack and we've that in be of patient is half for attack in the the experience perfect rate of most shared attacks and meets patients, to that of ORLADEYO with HAE matches half therapies many attacks teams This therapies, are good switching far But the of launching a other
once-daily person For to a how ORLADEYO feel able life, and patients them many oral, and anonymous that a of confidence, to continues get and with them shape you again my as expectations part be therapy experience with with an an patients, patients have to project a is recently market with asked of sizable conducted We transforming they HAE. of cohort research who level as live control an Themes give evidence letter ORLADEYO I changed describing normal exercise from confidence. common.
The also to experience. such you like to write me that were strong prescriber gave
of showed XXXX their expected to patients surveys treated by quarterly XX% with the of large they about HAE next Our over grow proportion in ORLADEYO consistently XX months. the allergists
have therapy injectable X,XXX treated from today, about also times XX% from have States. noted patients. press XXXX, including United predictions. ORLADEYO to patients the has X,XXX our more XX% there tried predicts. patients yet XXXX, Over release X,XXX providers allergists XXX physician But the in ORLADEYO, research treaters expect in prescribed XXXX diagnosed of prescribed clearly, an our we growth just of of our care from prophylaxis.
By our by come free means their number switched grew as the over end about many the for on year product surveys tracking the As of in long-term least switches or and next have over ORLADEYO at HAE for Currently, in U.S. prescribers new with patients not market ORLADEYO prophylaxis. XXXX, health opportunity program ORLADEYO. that over is but been on now in other X/X of paid That
front us growing is in it the opportunity pass ORLADEYO to get way lives is than of behind describe going to and there. more performance. us, changing body how patients' us of to evidence financial Anthony have about I'll our We help
